Skip to main content
Equibles
PRTA logo

PRTA · Prothena Corp Public Ltd Co

Track PRTA — free

Use PRTA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about PRTA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$8.86 -0.22 (-2.42%) At close · Aug 14
Market Cap
$454.85M
Shares
51.34M

Prothena Corp Public Ltd Co Earnings Call Transcripts

Every quarterly earnings call for Prothena Corp Public Ltd Co (PRTA) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲32% $256,000 −$21.55M '19 Q4 20-02-12 ▲16.8% $195,000 −$26.28M '20 Q2 20-08-06 ▼23.4% $157,000 −$30.58M '20 Q3 20-11-04 ▲40.6% $360,000 −$30.72M '20 Q4 21-02-11 ▲225.6% $1.17M −$33.18M '21 Q4 22-02-17 ▲4159.6% $49.92M $6.35M '22 Q4 23-02-23 ▼99.4% $316,000 −$67.48M '23 Q4 24-02-15 ▲571.8% $2.12M −$57.96M '24 Q4 25-02-20 LATEST ▼99% $21,000 −$21.59M '25 Q4 26-02-19
Earnings call
FY25 · Q4
2026-02-19
Prothena Corp Public Ltd Co Q4 FY2025 Earnings Call
Confident tone CytoPe intracellular targeting technology PRX-12 and transferrin receptor platform Partner program milestones and economics
Revenue
$21,000*
▼ 99% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q4
2025-02-20
Prothena Corp Public Ltd Co Q4 FY2024 Earnings Call
Positive tone PRX-12 Anti-A-beta Alzheimer's Program PRX-123 Dual Vaccine Commercial Build-Out and Launch Readiness
Revenue
$2.12M*
▲ 571.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q4
2024-02-15
Prothena Corp Public Ltd Co Q4 FY2023 Earnings Call
Positive tone PRX012 in Alzheimer's disease Birtamimab / AFFIRM-AL Phase 3 in AL Amyloidosis Prasinezumab (Roche partnership) and PADOVA readout
Revenue
$316,000*
▼ 99.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q4
2023-02-23
Prothena Corp Public Ltd Co Q4 FY2022 Earnings Call
Revenue
$49.92M*
▲ 4159.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q4
2022-02-17
Prothena Corp Public Ltd Co Q4 FY2021 Earnings Call
Revenue
$1.17M*
▲ 225.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q4
2021-02-11
Prothena Corp Public Ltd Co Q4 FY2020 Earnings Call
Revenue
$360,000
▲ 40.6% YoY
Diluted EPS
$-0.77
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Prothena Corp Public Ltd Co Q3 FY2020 Earnings Call
Revenue
$157,000
▼ 23.4% YoY
Diluted EPS
$-0.77
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Prothena Corp Public Ltd Co Q2 FY2020 Earnings Call
Revenue
$195,000
▲ 16.8% YoY
Diluted EPS
$-0.66
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-12
Prothena Corp Public Ltd Co Q4 FY2019 Earnings Call
Revenue
$256,000
▲ 32% YoY
Diluted EPS
$-0.54
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–9 of 9 earnings calls
Key facts CIK 1559053 CUSIP G72800108 13F (30d) 181 filings 177 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)